An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Tenaya Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Tenaya Therapeutics, a biotechnology firm focused on heart disease therapies, has announced its participation in several investor conferences. Key events include the Cowen 2nd Annual Genetic Medicines Summit on February 3, 2022, and the SVB Leerink Global Healthcare Conference on February 18, 2022. The company aims to develop curative treatments addressing genetic and prevalent heart conditions through gene therapy, cellular regeneration, and precision medicine. Founded by leading scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is committed to advancing heart disease treatment.
Positive
None.
Negative
None.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced participation at several upcoming investor conferences.
Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. For more information, visit www.tenayatherapeutics.com.
What is Tenaya Therapeutics' participation in investor conferences scheduled for 2022?
Tenaya Therapeutics will participate in several investor conferences, including the Cowen 2nd Annual Genetic Medicines Summit on February 3, 2022, and the SVB Leerink Global Healthcare Conference on February 18, 2022.
When is the Cowen 2nd Annual Genetic Medicines Summit featuring Tenaya Therapeutics?
The Cowen 2nd Annual Genetic Medicines Summit is scheduled for Thursday, February 3, 2022, at 12:00 p.m. ET.
What are the key product platforms of Tenaya Therapeutics?
Tenaya Therapeutics focuses on three key product platforms: Gene Therapy, Cellular Regeneration, and Precision Medicine, aimed at treating heart disease.
Which company founded Tenaya Therapeutics and what is its mission?
Tenaya Therapeutics was founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, with a mission to develop curative therapies for heart disease.
What type of therapies does Tenaya Therapeutics develop?
Tenaya Therapeutics develops curative therapies that target the underlying drivers of heart disease, including therapies for rare genetic disorders and more common heart conditions.
